Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 F

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced certain unaudited preliminary financial results for the first quarter ended March 31, 2023. The Company is also affirming financial guidance for the year ending December 31, 2023, which was previously...

Related Keywords

United States ,America ,Chintu Patel ,Drug Administration ,Saol International ,Exchange Commission ,Amneal Pharmaceuticals Inc ,Amneal Group ,Amneal Pharmaceuticals ,Preliminary Financial Results ,First Quarter Ended March ,Co Chief Executive ,Current Report ,Term Loan ,Rondo Term Loan ,Full Year ,Securities Litigation Reform Act ,Common Stock ,Annual Report ,Loss Before Income Taxes ,Months Ended March ,Preliminary Range ,Saol International Limited ,Puniska Healthcare ,